{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:55:23Z","timestamp":1777859723832,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Coadministration of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection and first generation anticonvulsants is currently not recommended due to a drug-drug interaction that could potentially lead to subtherapeutic DAA levels and subsequent treatment failure. Currently, there is limited data evaluating this interaction and timely treatment of HCV infection with DAAs is imperative to prevent liver-related morbidity and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective case series evaluating clinical cure of chronic HCV infection, defined as sustained virologic response (SVR) 12 weeks after completion of DAA therapy, in patients from three inner-city clinics who remained on first generation anticonvulsants during the treatment course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of five patients received standard dose DAAs for treatment of chronic HCV infection while being maintained on first generation anticonvulsants. The most common HCV genotype was 1a (80%), followed by 1b (20%). The majority of patients were treated with glecaprevir\/pibrentasvir (80%) for eight weeks and one patient was treated with ledipasvir\/sofosbuvir for 12 weeks. Anticonvulsant regimens consisted of carbamazepine, phenytoin, phenytoin plus phenobarbital, phenytoin plus levetiracetam, and phenobarbital plus lacosamide. All five patients achieved sustained virologic response (SVR) despite this drug-drug interaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although every effort to prevent concomitant use of DAAs and potent inducers should be made, clinical cure may still be achieved in patients whom cannot avoid this coadministration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0897190020977762","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T07:37:01Z","timestamp":1608017821000},"page":"495-499","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["When Coadministration Cannot Be Avoided: Real World Experience of Direct Acting Antivirals for the Treatment of Hepatitis C Virus Infection in Patients on First Generation Anticonvulsants"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5700-4676","authenticated-orcid":false,"given":"Kayla M.","family":"Natali","sequence":"first","affiliation":[{"name":"Saint Michael's Medical Center, Department of Pharmacy Services, Newark, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humberto R.","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA"},{"name":"St. Joseph's University Medical Center, Department of Pharmacy Services, Paterson, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihad","family":"Slim","sequence":"additional","affiliation":[{"name":"Saint Michael's Medical Center, Division of Infectious Diseases, Newark, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"bibr1-0897190020977762","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.07.035"},{"key":"bibr2-0897190020977762","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1519392"},{"key":"bibr3-0897190020977762","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.10.014"},{"key":"bibr4-0897190020977762","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"bibr5-0897190020977762","unstructured":"Mavyret [package insert]. AbbVie; 2018."},{"key":"bibr6-0897190020977762","unstructured":"Epclusa [package insert]. Gilead Sciences; 2016."},{"key":"bibr7-0897190020977762","unstructured":"Harvoni [package insert]. Gilead Sciences; 2017."},{"key":"bibr8-0897190020977762","unstructured":"Zepatier [package insert]. Merck & Co; 2016."},{"key":"bibr9-0897190020977762","unstructured":"Vosevi [package insert]. Gilead Sciences; 2018."},{"key":"bibr10-0897190020977762","unstructured":"Daklinza [package insert]. Bristol-Myers Squibb Company; 2017."},{"key":"bibr11-0897190020977762","unstructured":"Olysio [package insert]. Janssen Therapeutics; 2013."},{"key":"bibr12-0897190020977762","unstructured":"Viekira Pak [package insert]. AbbVie; 2014."},{"key":"bibr13-0897190020977762","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015581848"},{"key":"bibr14-0897190020977762","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.10.027"},{"key":"bibr15-0897190020977762","unstructured":"AASLD-IDSA. Recommendations for when and in whom to initiate hepatitis C therapy. Accessed November 6, 2019. https:\/\/www.hcvguidelines.org\/evaluate\/when-whom"},{"key":"bibr16-0897190020977762","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0261-7"},{"key":"bibr17-0897190020977762","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.06204.x"},{"issue":"1526","key":"bibr18-0897190020977762","first-page":"121","volume":"59","year":"2017","journal-title":"Med Lett Drugs Ther"},{"key":"bibr19-0897190020977762","doi-asserted-by":"publisher","DOI":"10.2174\/157015910792246254"},{"key":"bibr20-0897190020977762","unstructured":"Tegretol [package insert]. Novartis Pharmaceutical Corporation; 2009."},{"key":"bibr21-0897190020977762","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.7.965"},{"key":"bibr22-0897190020977762","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.07.002"},{"key":"bibr23-0897190020977762","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.04.004"},{"key":"bibr24-0897190020977762","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.010"},{"key":"bibr25-0897190020977762","unstructured":"Vosevi [package insert]. Gilead Sciences; 2017."},{"key":"bibr26-0897190020977762","unstructured":"Cardinal Health\u00ae 2019. All rights reserved. Accessed August 27, 2019. cardinalhealth.com\/en.html"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190020977762","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190020977762","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190020977762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:36:25Z","timestamp":1777509385000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190020977762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1177\/0897190020977762"],"URL":"https:\/\/doi.org\/10.1177\/0897190020977762","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,15]]}}}